The drawbacks of being left-handed are rarely more apparent than when you’re in grade school. If you’re part of the club, then you know our personal vendetta against spiral-bound notebooks and binders ...

Left-handers are more competitive than right-handers, according to a new study published in the journal Scientific Reports. The findings may help explain why left-handedness has persisted throughout ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

"Humans must always retain authority over life-and-death decisions," says UN Secretary General Antonio Guterres, arguing that AI systems cannot be allowed to run free in the military field. Speaking ...

No matter how hard ideologues try to exclusively blame their political foes for acts of political violence, the truth is that violent extremists today emerge from across the political spectrum. We ...

There’s a popular idea that our brains have two sides with two roles. The left side of the brain is analytical and concerned with facts and figures, whereas the right side of the brain is creative, ...

Do you know what it means to "drive left of center"? No matter if it pops up in a driver's ed class, an accident report, or a traffic stop, it's a phrase drivers need to be familiar with. Put simply, ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.